A weekly summary of insider trading highlighting a few notable buying and selling by investors, directors and executives. The ...
Sandra Leung began her legal career prosecuting homicides, a formative experience that she once said taught her "to make ...
William Blair reduced their Q1 2026 EPS estimates for Bristol-Myers Squibb in a research report issued to clients and ...
Bristol Myers Squibb Co. said Cari Gallman, the company’s executive vice president for corporate affairs, will become its ...
Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...
This was the stock's third consecutive day of losses.
Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...
Bristol Myers Squibb has bolstered its case for Opdivo to be used as a pre-operative treatment for non-small cell lung cancer ...
GlobalData on MSN6d
Bristol Myers Squibb’s Sotyktu shows consistent safety profile in psoriasis trialUS-based pharmaceutical company Bristol Myers Squibb (BMS) has reported results from the POETYK PSO long-term extension (LTE) ...
SAN DIEGO, CALIFORNIA / ACCESS Newswire / February 18, 2025 / Rancho BioSciences, the premier tech-enabled data science ...
Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...
Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report) today. The company’s shares closed yesterday at $54.98. See what stocks ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback